Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Inhibit Tumor
100%
Tumor Growth
100%
Vascular Endothelial Growth Factor
100%
Xenograft Model
100%
Receptor Blockade
100%
Inhibitor Resistance
100%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
100%
Erlotinib
71%
Acquired Resistance
57%
Primary Resistance
57%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
42%
Gefitinib
42%
Vandetanib
42%
Dual Inhibition
42%
Epidermal Growth Factor Receptor Signaling
28%
Bevacizumab
28%
Non-small Cell Lung Cancer Patients
28%
Erlotinib Resistance
28%
Tumor
14%
Tumor Cells
14%
KRAS mutation
14%
Tumor Regression
14%
Host Specificity
14%
Enhanced Activity
14%
In Vitro Activity
14%
HCC827
14%
Endothelial Proliferation
14%
EGFR mutation
14%
Inhibitor Sensitivity
14%
Stromal Vascular Fraction
14%
MET Amplification
14%
Secondary mutation
14%
KRAS mutant
14%
A549 Xenograft
14%
EGFR-TKI Resistance
14%
K-Ras
14%
Tumor-derived
14%
Combined Blockade
14%
Medicine and Dentistry
Tumor Progression
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Epidermal Growth Factor Receptor
100%
Xenograft
100%
Vasculotropin Receptor
100%
Receptor Blocking
100%
Erlotinib
87%
Vasculotropin
50%
Gefitinib
37%
Vandetanib
37%
Neoplasm
25%
Non Small Cell Lung Cancer
25%
Bevacizumab
25%
In Vitro
12%
Tumor Cell
12%
Tumor Regression
12%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Growth
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Epidermal Growth Factor Receptor
100%
Vasculotropin Receptor
100%
Erlotinib
87%
Vasculotropin
50%
Neoplasm
37%
Gefitinib
37%
Vandetanib
37%
Non Small Cell Lung Cancer
25%
Bevacizumab
25%
Tumor Regression
12%
Biochemistry, Genetics and Molecular Biology
Tumor Progression
100%
Epidermal Growth Factor Receptor
100%
Growth Factor Receptor Inhibitor
100%
VEGF Receptors
100%
Receptor Blocking
100%
Erlotinib
53%
Vascular Endothelial Growth Factor
30%
Receptor Tyrosine Kinase Inhibitors
30%
Gefitinib
23%
Vandetanib
23%
Bevacizumab
15%
KRAS
7%